Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
07 December 2017 - 12:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that
Wendy Yarno has been elected to the company's Board of Directors.
Wendy Yarno has over 25 years of experience in the pharmaceutical
industry highlighted by her tenure at Merck & Co. where she
served as chief marketing officer.
At Merck, Ms. Yarno led a global organization
charged with all aspects of supporting pre- and post-launch
commercialization of pharmaceuticals in more than 20 therapeutic
areas. She also previously served as General Manager,
Cardiovascular/Metabolic U.S. Business Unit, where she had P&L
responsibility for Merck's largest therapeutic area, and as Senior
Vice President, Human Resources. Earlier in her career she was vice
president of the women's health care franchise for Johnson &
Johnson's Ortho-McNeil Pharmaceutical subsidiary.
Dr. J. Joseph Kim, President and CEO, said,
“Wendy Yarno joins Inovio at a critical point in our development as
we pivot to a late-stage clinical company with significant big
pharma partnerships. Her expertise and counsel will be invaluable
to Inovio as we move toward product commercialization and
additional industry alliances.”
Wendy Yarno has served on the boards of
successful biopharmaceutical and medical technology companies,
including Medivation Inc., St. Jude Medical Inc., and Durata
Therapeutics Inc. She currently serves on the boards of Alder
Biopharmaceuticals, Aratana Therapeutics Inc. and MyoKardia, Inc.
Ms. Yarno holds a master's degree in business administration from
Temple University's Fox School of Business and a bachelor's degree
in business administration from Portland State University.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, Regeneron, Genentech, The Wistar Institute, University
of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life
Sciences, ApolloBio Corporation, Drexel University, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S. Military
HIV Research Program, and Laval University. For more information,
visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs, including the planned initiation
and conduct of clinical trials and the availability and timing of
data from those trials, and the sufficiency of our capital
resources. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials and product development programs, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA vaccines, our ability to
support our pipeline of SynCon® active immunotherapy and vaccine
products, the ability of our collaborators to attain development
and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by the company or its collaborators, including
alternatives that may be more efficacious or cost effective than
any therapy or treatment that the company and its collaborators
hope to develop, issues involving product liability, issues
involving patents and whether they or licenses to them will provide
the company with meaningful protection from others using the
covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2016, our Form 10-Q for the period
ended September 30, 2017, and other regulatory filings we make from
time to time. There can be no assurance that any product candidate
in Inovio's pipeline will be successfully developed, manufactured
or commercialized, that final results of clinical trials will be
supportive of regulatory approvals required to market licensed
products, or that any of the forward-looking information provided
herein will be proven accurate. Forward-looking statements speak
only as of the date of this release, and Inovio undertakes no
obligation to update or revise these statements, except as may be
required by law.
CONTACTS:Investors/Media: Jeff
Richardson, Inovio Pharmaceuticals, 267-440-4211,
jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2024 to May 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From May 2023 to May 2024